被动抬腿试验联合经胸超声心动图指导脓毒性休克早期液体复苏的临床价值
该前瞻性随机对照试验纳入2017年1月至2018年10月中日友好医院收治的74例脓毒性休克患者,随机分为对照组与试验组各37例,均经验性使用广谱抗生素并经锁骨下静脉导管进行液体复苏。对照组采用快速补液,试验组根据被动抬腿试验联合经胸超声心动图测得的每搏量变异度指导补液:每搏量变异度≥15%判定有容量反应性并给予液体负荷,<15%判定无容量不足并给予限制性补液。两组复苏目标均为6小时内同时满足中心静脉压8-12 mmHg、平均动脉压≥65 mmHg、尿量≥0.5 mL×kg-1×h-1、中心静脉血氧饱和度≥0.70,未达标者使用血管活性药物。结果显示试验组6小时乳酸、氧合指数、中心静脉血氧饱和度及48小时C反应蛋白均优于对照组,肺水肿发生率更低,住院时间更短,但两组住院病死率无显著差异。
要点
- 脓毒性休克患者以被动抬腿试验联合经胸超声心动图测每搏量变异度指导补液:每搏量变异度≥15%给予液体负荷,<15%给予限制性补液。
- 该策略较传统快速补液在6小时改善乳酸(2.52±1.15 vs. 3.89±1.42 mmol/L)、氧合指数(338.14±27.47 vs. 303.35±22.52 mmHg)和中心静脉血氧饱和度(0.70±0.04 vs. 0.63±0.05),均P<0.01。
- 该策略使48小时C反应蛋白更低(110.12±39.80 vs. 137.98±31.23 mg/L,P<0.01),肺水肿发生率更低(13.5%(5/37)vs. 37.8%(14/37),P<0.01),住院时间更短(21.47±5.58 vs. 28.33±4.93天,P<0.01)。
- 两组住院病死率无显著差异(18.9%(7/37)vs. 18.9%(7/37),P>0.05)。
- 两组平均动脉压差异无统计学意义(78.76±5.22 vs. 76.35±6.66 mmHg,P>0.05)。
适用人群与场景
- 2017年1月至2018年10月中日友好医院收治的脓毒性休克患者74例,随机分为对照组和试验组各37例。
诊断标准与关键阈值
- 以经胸超声心动图测得的每搏量变异度判断容量反应性:每搏量变异度≥15%认为有容量反应性,给予液体负荷;每搏量变异度<15%认为无容量不足,给予限制性补液。
- 两组液体复苏目标为6小时内同时满足:中心静脉压8-12 mmHg(1 mmHg=0.133 kPa)、平均动脉压≥65 mmHg、尿量≥0.5 mL×kg-1×h-1、中心静脉血氧饱和度≥0.70。
处置流程与药物剂量
- 两组均经验性使用广谱抗生素,并经锁骨下静脉导管进行液体复苏。
- 对照组给予快速补液;试验组根据被动抬腿试验联合经胸超声心动图结果补液:被动抬腿试验前后用经胸超声心动图测每搏量,以每搏量变异度判断容量反应性,≥15%给予液体负荷,<15%给予限制性补液。
- 两组复苏目标为6小时内同时满足中心静脉压8-12 mmHg、平均动脉压≥65 mmHg、尿量≥0.5 mL×kg-1×h-1、中心静脉血氧饱和度≥0.70;未达到治疗目标时使用血管活性药物。
研究设计与关键结果
- 前瞻性随机对照试验,74例脓毒性休克患者,对照组与试验组各37例;两组性别、年龄、体重及病因构成无显著差异,基线均衡。
- 治疗6小时后两组平均动脉压、乳酸、氧合指数、中心静脉血氧饱和度均较补液前改善;试验组与对照组平均动脉压差异无统计学意义(78.76±5.22 vs. 76.35±6.66 mmHg,P>0.05),其余三项试验组显著优于对照组:乳酸(2.52±1.15 vs. 3.89±1.42 mmol/L)、氧合指数(338.14±27.47 vs. 303.35±22.52 mmHg)、中心静脉血氧饱和度(0.70±0.04 vs. 0.63±0.05),均P<0.01。
- 治疗48小时后两组C反应蛋白均较补液前降低,试验组优于对照组(110.12±39.80 vs. 137.98±31.23 mg/L,P<0.01)。
- 胸部CT显示试验组肺水肿发生率显著低于对照组(13.5%(5/37)vs. 37.8%(14/37),P<0.01)。
- 试验组住院时间短于对照组(21.47±5.58 vs. 28.33±4.93天,P<0.01);两组住院病死率无显著差异(18.9%(7/37)vs. 18.9%(7/37),P>0.05)。
证据类型、等级与局限
- 证据类型:前瞻性随机对照试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,与传统快速补液相比,被动抬腿试验联合经胸超声心动图指导的早期液体复苏策略可更好地改善脓毒性休克患者组织器官的灌注与氧合水平,避免快速补液导致的肺水肿,缩短住院时间,但对住院病死率无显著影响。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: To explore the clinical value of early fluid resuscitation guided by passive leg-raising test (PLR) combined with transthoracic echocardiography (TTE) in patients with septic shock.
METHODS: A prospective randomized controlled trial (RCT) was conducted. Seventy-four patients with septic shock admitted to China-Japan Friendship Hospital from January 2017 to October 2018 were enrolled. The patients were randomly divided into control group and experimental group with 37 patients in each group. Both groups of patients were treated with broad-spectrum antibiotics empirically, while received fluid resuscitation via the subclavian vein catheter. The patients of control group were given rapid fluid replacement, and those of experimental group received fluid replacement according to result of PLR combined with TTE. The stroke volume (SV) was measured by TTE before and after PLR, volumetric response of patients was judged by stroke volume variation (SVV). If the SVV ≥ 15%, it was considered that there was a volume responsiveness, and fluid loading was given. If SVV < 15%, it was considered that there was no volume shortage, and the restrictive fluid replacement was given. The goal of fluid resuscitation in both groups were to simultaneously meet the central venous pressure (CVP) of 8-12 mmHg (1 mmHg = 0.133 kPa), mean arterial pressure (MAP) ≥ 65 mmHg, urine volume ≥ 0.5 mL×kg-1×h-1, and central venous blood oxygen saturation (ScvO2) ≥ 0.70 within 6 hours. Vasoactive drugs were used when the patients could not achieve the treatment goals. The MAP, lactic acid (Lac), oxygenation index (PaO2/FiO2) and ScvO2 of the patients were determined at 6 hours of treatment, and serum C-reactive protein (CRP) and chest CT were reviewed at 48 hours of treatment, and compared with those before treatment. The total hospital stay and the mortality were recorded.
RESULTS: There was no significant difference in gender, age, body weight and etiological structure between the two groups, which indicated that the baseline data were generally balanced. There was no statistical difference in MAP, Lac, PaO2/FiO2, ScvO2 and CRP before infusion between the two groups. After 6 hours of treatment, the MAP, Lac, PaO2/FiO2 and ScvO2 of the two groups were all better than those before infusion. Except for the difference in MAP between the experimental group and the control group (mmHg: 78.76±5.22 vs. 76.35±6.66, P > 0.05), the other three parameters in the experimental group were significantly better than those in the control group [Lac (mmol/L): 2.52±1.15 vs. 3.89±1.42, PaO2/FiO2 (mmHg): 338.14±27.47 vs. 303.35±22.52, ScvO2: 0.70±0.04 vs. 0.63±0.05, all P < 0.01]. After 48 hours of treatment, CRP levels of both groups were lower than those before infusion, and the experimental group was better than the control group (mg/L: 110.12±39.80 vs. 137.98±31.23, P < 0.01). Chest CT showed that the incidence of pulmonary edema in the experimental group was significantly lower than that in the control group [13.5% (5/37) vs. 37.8% (14/37), P < 0.01]. The hospital stay of the experimental group was shorter than that of the control group (days: 21.47±5.58 vs. 28.33±4.93, P < 0.01), but no significant difference in mortality was found between the two groups [18.9% (7/37) vs. 18.9% (7/37), P > 0.05].
CONCLUSIONS: Compared with the traditional rapid fluid replacement, early fluid resuscitation treatment strategies guided by the PLR combined with TTE, could better improve perfusion and oxygenation level of tissues and organs, avoid pulmonary edema caused by rapid fluid replacement, shorten the hospital stay in patients with septic shock, but had no significant effect on hospital mortality.
参考来源
- Li G, Wei F, Zhang G, et al. [Clinical value of early liquid resuscitation guided by passive leg-raising test combined with transthoracic echocardiography in patients with septic shock]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2019. PMID: 31109412. doi:10.3760/cma.j.issn.2095-4352.2019.04.008
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。